Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial
| Autor: | Peter Junker, Tove Lorenzen, Tonny Jensen, Mikkel Østergaard, Natalia Manilo, Henning Bliddal, Kristian Stengaard-Pedersen, Lykke Midtbøll Ørnbjerg, Tine Lottenburger, Marcin Ryszard Kowalski, Hans Christian Horn, Hanne Merete Lindegaard, I. Hansen, Ole Slot, Anette Jørgensen, Inger Lauge Johansen, Palle Ahlquist, Asta Linauskas, Annette Schlemmer, Lars Kjær Nielsen, Torkell Ellingsen, Peter Mosborg Pedersen, O Majgaard, Christian Gytz Ammitzbøll, Mette Yde Dam, Johnny Lillelund Raun, Merete Lund Hetland, Kim Hørslev-Petersen, Henrik Skjødt, Sophine B. Krintel |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Male Triamcinolone acetonide Denmark Gastroenterology Severity of Illness Index Arthritis Rheumatoid 0302 clinical medicine Absorptiometry Photon Bone Density Bone mineral General Medicine Middle Aged Multicenter Study Hand Bones Hand bone loss Rheumatoid arthritis Antirheumatic Agents Randomized Controlled Trial Disease Progression Drug Therapy Combination Female Digital X-ray radiogrammetry Algorithms medicine.drug Adult medicine.medical_specialty 03 medical and health sciences Rheumatology Double-Blind Method Internal medicine Journal Article medicine Adalimumab Humans 030203 arthritis & rheumatology business.industry medicine.disease Surgery Clinical trial Bone Diseases Metabolic 030104 developmental biology Methotrexate Multivariate Analysis Linear Models business |
| Zdroj: | Ørnbjerg, L M, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Hetland, M L, Slot, O, Nielsen, L K, Skjødt, H, Majgaard, O, Lorenzen, T, Horn, H C, Kowalski, M, Johansen, I L, Pedersen, P M, Manilo, N, Bliddal, H & OPERA Study Group 2017, ' Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial ', Clinical Rheumatology, vol. 36, no. 4, pp. 781-789 . https://doi.org/10.1007/s10067-016-3489-1 Ørnbjerg, L M, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Hetland, M L, OPERA Study Group & Lorenzen, T 2017, ' Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab-a substudy of the optimized treatment algorithm in early RA (OPERA) trial ', Clinical Rheumatology, vol. 36, no. 4, pp. 781-789 . https://doi.org/10.1007/s10067-016-3489-1 Ørnbjerg, L M, Østergaard, M, Jensen, T, Hørslev-Petersen, K, Stengaard-Pedersen, K, Junker, P, Ellingsen, T, Ahlquist, P, Lindegaard, H, Linauskas, A, Schlemmer, A, Dam, M Y, Hansen, I, Lottenburger, T, Ammitzbøll, C G, Jørgensen, A, Krintel, S B, Raun, J, Hetland, M L, OPERA Study Group, Slot, O, Nielsen, L K, Skjødt, H, Majgaard, O, Lorenzen, T, Horn, H C, Kowalski, M, Johansen, I L, Pedersen, P M, Manilo, N & Bliddal, H 2017, ' Hand bone loss in early rheumatoid arthritis during a methotrexate-based treat-to-target strategy with or without adalimumab : a substudy of the optimized treatment algorithm in early RA (OPERA) trial ', Clinical Rheumatology, vol. 36, no. 4, pp. 781–789 . https://doi.org/10.1007/s10067-016-3489-1 |
| DOI: | 10.1007/s10067-016-3489-1 |
| Popis: | This study aims to investigate 1-year hand bone loss (HBL 1-year) in early rheumatoid arthritis (RA) patients treated with a methotrexate (MTX) and intra-articular triamcinolone treat-to-target strategy +/− adalimumab and to determine if HBL 6months is associated with radiographic progression after 2 years. In a clinical trial (OPERA) of 180 treatment-naive early RA patients, bone mineral density (BMD) was estimated from hand radiographs with digital X-ray radiogrammetry (DXR) at baseline, after 6 (n = 90) and 12 months (n = 70) of follow-up. Baseline and 2-year radiographs were scored according to the Sharp/van der Heijde method. Baseline characteristics and HBL 6months (0–6 months changes in DXR-BMD) were investigated as predictors of structural damage by univariate linear (∆ total Sharp/van der Heijde score (TSS) as dependent variable) and logistic (+/−radiographic progression (∆TSS >0) as dependent variable) regression analyses. Variables with p 1-year data, HBL 1-year was median (interquartile range (IQR)) −1.9 (−3.3; −0.26 mg/cm 2) in the MTX + placebo group and −1.8 (−3.6; 0.06) mg/cm 2 in the MTX + adalimumab group, p = 0.98, Wilcoxon signed-rank. Increased HBL (compared to general population reference values) was found in 26/37 and 23/33 patients in the MTX + placebo and MTX + adalimumab groups, chi-squared = 0.99. In 90 patients with HBL 6months data and 2-year radiographic data, HBL 6months was independently associated with ∆TSS after 2 years (β = −0.086 (95% confidence interval = −0.15; −0.025) TSS unit/mg/cm 2 increase, p = 0.006) but not with presence of radiographic progression (∆TSS >0) (OR 0.96 (0.92–1.0), p = 0.10). In early RA patients treated with a methotrexate-based treat-to-target strategy, the majority of patients had increased HBL 1-year, irrespective of adalimumab; HBL 6months was independently associated with ∆TSS after 2 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|